Dr. Garo Armen

“Before we start, on today's call, I will cover six priorities, or I should say we will collectively cover six priorities. First, we are going to present to you the newest buckball data validating durable responses in historically untreatable cold tumors.”

“Today, we'll primarily focus on the significant progress we've made with our groundbreaking botensilimab program and its potential to transform cancer treatment across nine different solid tumor types that we've reported on so far.”

“We are absolutely thrilled to share the progress we've made at Agenus in advancing our deep immuno-oncology pipeline. Our portfolio is designed to address areas of high patient need and to unlock the large untapped market opportunity in cold and treatment-resistant cancers.”

“Once again, good morning and thank you for joining us yesterday for our third quarter update and numbers discussion. It is an exciting time for Agenus and we believe also for the field of immuno-oncology.”